Table 4.
Distribution of H. pylori eradication regimens according to family history, age group and cancer development status.
| Factors | H. pylori Eradication Regimen | |||||
|---|---|---|---|---|---|---|
| Standard Triple Therapy a | Sequential or Concomitant Therapy b | p-Value | ||||
| n | % | n | % | |||
| n = 1,757,599 | n = 127,566 | |||||
| Characteristics | ||||||
| Family history status | ||||||
| No | 1,483,863 | 84.4 | 107,309 | 84.1 | 0.004 | |
| Yes | 273,736 | 15.6 | 20,257 | 15.9 | ||
| Age group | ||||||
| ≥75 years | 63,261 | 3.6 | 2437 | 1.9 | <0.001 | |
| 70–74 years | 92,193 | 5.2 | 3841 | 3.0 | ||
| 65–69 years | 223,100 | 12.7 | 10,609 | 8.3 | ||
| 60–64 years | 202,709 | 11.5 | 11,110 | 8.7 | ||
| 55–59 years | 387,240 | 22.0 | 25,883 | 20.3 | ||
| 50–54 years | 271,491 | 15.4 | 22,461 | 17.6 | ||
| 45–49 years | 227,723 | 13.0 | 21,077 | 16.5 | ||
| 40–44 years | 289,882 | 16.5 | 30,148 | 23.6 | ||
| Cancer development | ||||||
| No | 1,746,513 | 99.4 | 126,745 | 99.4 | 0.312 | |
| Yes | 11,086 | 0.6 | 821 | 0.6 | ||
| Risk of gastric cancer development | ||||||
| Crude HR | Reference | 1.22 (1.13–1.31) | ||||
| Adjusted HR c | Reference | 1.62 (1.16–2.25) | ||||
a Standard triple therapy was defined as the concomitant prescription of proton pump inhibitors (PPI), clarithromycin, and amoxicillin. b Sequential therapy was defined as the concomitant prescription of PPI and amoxicillin for 5 days followed by PPI, clarithromycin, and metronidazole for 5 days. Concomitant therapy was defined as the concomitant prescription of PPI, clarithromycin, amoxicillin, and metronidazole. c Hazard ratios from the multivariate model were adjusted for age at screening, sex, obesity, smoking habit, alcohol consumption, physical activity, and comorbidities.